Anticancer fusion protein comprising TRAIL and interferon

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9161991
APP PUB NO 20130251676A1
SERIAL NO

13989969

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

A fusion protein comprising domain (a) which is a functional fragment of hTRAIL protein sequence, which fragment begins with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment having at least 70% sequence identity; and domain (b) which is a sequence of an immunostimulating effector peptide, wherein the sequence of domain (b) is attached at the C-terminus or N-terminus of domain (a). The fusion protein can be used for the treatment of cancer diseases.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
ADAMED PHARMA S A05-152 CZOSNOW

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Żerek, Bartłomiej Dąbrowa, PL 1 3
Lemke, Krzysztof Kazimierz Gdynia, PL 2 8
Pawlak, Sebastian Warszawa, PL 3 9
Pieczykolan, Jerzy Szczepan Radecznica, PL 6 24

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Apr 20, 2027
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00